Experience with clarithromycin as antineoplastic therapy for extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT-lymphoma) outside of clinical trials: Real-world data from the University of Vienna

Hematol Oncol. 2020 Aug;38(3):409-411. doi: 10.1002/hon.2738. Epub 2020 Apr 29.

Authors

Antonia Pokorny¹, Barbara Kiesewetter¹, Markus Raderer¹

Affiliation

¹ Department of Internal Medicine I, Clinical Division of Oncology, Medical University Vienna, Vienna, Austria.

PMID: 32347560
DOI: 10.1002/hon.2738

No abstract available

Keywords: MALT-lymphoma; antineoplastic activity; clarithromycin.

Publication types

Letter

MeSH terms

Aged
Antineoplastic Agents / therapeutic use*
Clarithromycin / therapeutic use*
Female
Follow-Up Studies
Humans
Lymphoma, B-Cell, Marginal Zone / classification*
Lymphoma, B-Cell, Marginal Zone / drug therapy*
Lymphoma, B-Cell, Marginal Zone / pathology
Male
Middle Aged
Prognosis
Retrospective Studies

Substances

Antineoplastic Agents
Clarithromycin